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We screened for the presence of inborn errors of metabolism (IEM) in 187 children (105
males; 82 females, ages 4–14 years old) who presented with confirmed features of autism
spectrum disorder (ASD). Twelve patients (7%) manifested increased 3-hydroxyisovaleric
acid (3-OH-IVA) excretion in urine, and minor to significant improvement in autistic
features was observed in seven patients following supplementation with biotin. Five
diagnoses included: Lesch Nyhan syndrome (2), succinic semialdehyde dehydrogenase
(SSADH) deficiency (2), and phenylketonuria (1) (2.7%). Additional metabolic disturbances
suggestive of IEMs included two patients whose increased urine 3-OH-IVA was
accompanied by elevated methylcitrate and lactate in sera, and 30 patients that showed
abnormal glucose-loading tests. In the latter group, 16/30 patients manifested increased
sera beta hydroxybutyrate (b-OH-b) production and 18/30 had a paradoxical increase of
sera lactate. Six patients with elevated b-OH-b in sera showed improved autistic features
following implementation of a ketogenic diet (KD). Five patients showed decreased serum
ketone body production with glucose loading. Twelve of 187 patients demonstrated
non-specific MRI pathology, while 25/187 had abnormal electroencephalogram (EEG)
findings. Finally, family history was positive for 22/187 patients (1st or 2nd degree
relative with comparable symptomatology) and consanguinity was documented for 12/187
patients. Our data provide evidence for a new biomarker (3-OH-IVA) and novel treatment
approaches in ASD patients. Concise 1 sentence take-home message: Detailed metabolic
screening in a Greek cohort of ASD patients revealed biomarkers (urine 3-hydroxyisovaleric
acid and serum b-OH-b) in 7% (13/187) of patients for whom biotin supplementation or
institution of a KD resulted in mild to significant clinical improvement in autistic features.
Keywords: autism, inborn errors of metabolism, biotin, ketogenic diet, 3-hydroxyisovaleric acid, Lesch-Nyhan
disease, succinic semialdehyde dehydrogenase deficiency, phenylketonuria
INTRODUCTION
Numerous pathologies (Fragile X, syndromes of congenital infec-
tion, vaccinations, perinatal damage, and others) have been dis-
cussed as potential etiologies associated with autistic behavior
and/or autism spectrum disorder (ASD) (Mazzoko et al., 1998;
Gallagher and Goodman, 2010), and an expanding literature
has demonstrated more frequent associations between inborn
errors of metabolisms (IEMs) and ASD (Weissman et al., 2008;
Sempere et al., 2010). Recent reports have highlighted a growing
association between ASDs and respiratory chain abnormalities,
including complex III/IV deficiency and MELAS syndrome, as
well as glucose-6-phosphate dehydrogenase deficiency (Guevara-
Campos et al., 2010; Chauhan et al., 2011). Further, a number
of reports suggest metabolic derangements in ASD patients that
are suggestive of IEM, such as abnormalities of glucose oxida-
tion and utilization, among others (Haznedar et al., 2006; Zhao
et al., 2010). In these cases, however, it is difficult to conclusively
identify whether the manifestation of ASD on the background
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of the IEM is a primary or secondary pathology. Despite the
increased number of IEM, recent work (Schiff et al., 2010) sug-
gested that a careful clinical evaluation is more crucial than
systematic metabolic investigations but this aspect should be
tested through a large population based prospective study assess-
ing the benefits of routine metabolic screening in non-syndromic
autistic spectrum disorders.
Greece represents a country for which a number of popula-
tions reside in relative geographic isolation. This is especially true
for the Greek islands, where previous studies have documented
a large number of patients for whom indeterminate neurologi-
cal features associate with a small number of IEMs (Evangeliou
et al., 2001). Many of these patients manifest features of ASD,
occasionally associated with a positive family history and/or con-
sanguinity. In order to extend our earlier work, we examined a
cohort of these patients on the island of Crete in order to ascer-
tain the incidence of IEMs and metabolic disturbances, and the
corresponding link to ASD. The current report summarizes the
results of our investigations.
MATERIALS AND METHODS
We evaluated 187 children (105 males, 82 females; ages 4–14
years) who presented with ASD. The differential diagnosis was
based upon DSM-IV criteria for pervasive developmental disor-
ders (PDDs; Kim et al., 2010; see also Table 1).
Patients with identified ASD etiologies (e.g., perinatal dam-
age, CNS infection, CNS tumor, or chromosomal abnormali-
ties related to known neurogenetic disorders such as Angelman
syndrome) were excluded from evaluation. Further, patients with
Table 1 | Childhood Autism Rating Scale (CARS) (Schopler et al.,
1980).
1. Disorder in human relationship (i.e., no appreciation by the
individual of the interest that other people show for him/her)
2. Mimicking (i.e., the extent to which the patient mimics)
3. Improper emotions (e.g., the unsuitable timing of emotions such
as laughing and crying)
4. Bizarre use of bodily movements and persistence to stereotypy
5. Peculiar relations with objects (e.g., correct use of objects)
6. Resistance to changes in the environment
7. Idiosyncratic optic reactions (e.g., avoidance of eye contact)
8. Idiosyncratic acoustic reactions (avoidance of or exaggerated
reaction to noise)
9. Putting objects in mouth, licking, smelling, and rubbing
10. Stress reactions (e.g., intensity of repression)
11. Verbal communication (e.g., lack of speech, echolalia, replacement
of personal pronouns)
12. Nonverbal communication (e.g., use of or response to gestures)
13. Extreme levels of activity (e.g., apathy or hyperactivity)
14. Mental function (i.e., lack of homogeneity of cognitive
characteristics)
15. General impressions (e.g., general ranking)
Legend to table: ranking of symptoms: 1, normal for age; 2, mild disorder; 3,
moderate disorder; 4, serious disorder. For each of these 15 items a cumulative
score is derived by summing 1–4 points for each item.
otorhinal or ocular abnormalities, as well as failure to thrive, were
also excluded.
At admission, we recorded detailed family histories (e.g.,
additional affected individuals, consanguinity, repetitive miscar-
riages, etc.) as well as dietary habits of the patients (symp-
toms following ingestion of certain foods and/or prolonged
fasting, tendency to dietary avoidances). All subjects underwent
detailed clinical and psychiatric examination, and anthropo-
morphic data was obtained. Laboratory investigations included:
complete blood count, blood biochemical evaluations (elec-
trolytes, glucose, transaminases, CPK, LDH, cholesterol, triglyc-
erides, thyroid hormones), electrocardiogram (ECG), and elec-
troencephalogram (EEG). These were followed by more specific
examinations, including: serum amino acids, carnitine, urine
purines and pyrimidines, urine amino and organic acids, urine
mucopolysaccharides and oligosaccharides, cytogenetic analysis,
and glucose loading test. For the latter, blood was obtained
for determination of lactic acid, pyruvate, and β-hydroxybutyric
acid (b-OH-b) following an 8 h fast, after which subjects
received a 10% glucose bolus (2 g/kg of body weight, maxi-
mum 50 g). Sixty minutes post glucose administration, blood was
obtained for determination of the same metabolites. In selected
patients, more detailed analyses included lysosomal enzymol-
ogy, guanidinoacetate-n-methyltransferase (GAMT) assay and
biopsy of skeletal muscle for assessment of various mitochondrial
enzymes.
RESULTS
CONFIRMED DIAGNOSES
We identified two patients with Lesch Nyhan syndrome, two
patients with succinic semialdehyde dehydrogenase (SSADH)
deficiency, and a single patient with phenylketonuria. Thus, con-
firmed diagnoses in ASD patients for a known IEM was 2.7% of
the total subject number investigated.
BIOCHEMICAL ABNORMALITIES SUGGESTIVE OF IEM
For 12/187 (7%) of patients, urinary 3-hydroxyisovaleric acid
(3-OH-IVA) was elevated and sera methylcitrate and lactate levels
were also elevated in two of these patients. Despite these bio-
chemical abnormalities, defects in biotinidase, or holocarboxylase
synthetase (Watanabe et al., 2005) could not be demonstrated in
either sera or fibroblasts. Of interest, none of these 12 patients was
undergoing valproate intervention, the latter a potential source
of 3-OH-IVA elevation in urine (Silva et al., 2001). Despite an
absence of confirmatory enzyme deficiencies in these 12 patients,
we nonetheless opted to treat empirically with biotin for 3 weeks,
2× 10mg and then for 6 months at 2× 5mg, which led to a
clear therapeutic benefit in 7/13 consisting of improvement in
the Childhood Autism Rating Scale (CARS; Table 2). For those
benefiting from biotin intervention, the most impressive outcome
centered on a 42 month-old boy whose severe ASD was com-
pletely ameliorated following biotin intervention. This patient
was subsequently followed for 5 years, and cessation of biotin
intervention (or placebo replacement) resulted in the rapid return
of ASD-like symptomatology. This patient currently attends pub-
lic school without any clinical sequelae and remains on biotin at
20mg/d.
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Table 2 | ASD patients with increased urinary 3-hydroxyisovaleric acid and biotin supplemented.
Pat. no 3-OH-IVA
mmol/mol/
creatinine
(normal
range
10.4–67.0)
Cardinal symptoms Non-autistic
symptoms
Pre-CARS Age of
treatment
initiation
in years
Post-CARS
6 months
after
treatment
initiation
Cardinal
symptoms
6 months
after
treatment
initiation
1 171 H, AD, not responding to verbal cues,
no speech, stereotypies, aggressive
or self-injurious behavior, fascination
with repetitive movement
No 44 3 19 No
symptoms
2 161 H, AD, difficulty interacting with other
people, compulsive behavior, speech
abnormal in content and quality
Positive family
history
44 3 29 Very mild H,
very mild AD,
amelioration
of all other
symptoms
3 200 No speech, H, AD, compulsive
behavior, stereotypies
Consanguinity 41 4 29 Very mild H,
very mild AD,
amelioration
of all other
symptoms
4 115 Compulsive behavior, abnormal
speech, H, AD, fascination with
repetitive movement
No 41 4 32 Improvement
in all
symptoms
5 145 Speech abnormal in content and
quality, H, AD
No 40 5 31 Improvement
in all
symptoms
6 145 Abnormal speech, H, AD Pathologic
EEG
38 2,5 30 Improvement
in all
symptoms
7 170 H, AD, Compulsive behavior, not
responding to verbal cues, no speech,
preoccupation with parts of objects,
aggressive or self-injurious behavior
No 45 3 40 Still H and
AD, some
improvement
in speech
and behavior
8 182 Abnormal speech, H, AD, aggressive
or self-injurious behavior
No 41 5 41 No
improvement
9 175 Compulsive behavior, AD, abnormal
speech, stereotypies
No 39 6 39 No
improvement
10 128 Compulsive behavior, abnormal
speech, H, AD, fascination with
repetitive movement, stereotypies
No 41 4,5 41 No
improvement
11 135 No speech, stereotypies, compulsive
behavior, AD
No 41 4,4 41 No
improvement
12 119 No speech, compulsive behavior, AD,
aggressive or self-injurious behavior
No 38 5 38 No
improvement
Legend to table: >12 unit difference is considered significant improvement; 8–12 unit, average improvement; 2–8 units, minor improvement. Note that a score of
>30 on the CARS is indicative of autism. Patients were not undergoing adjuvant therapy during biotin intervention. Abbreviations: 3-OH-IVA, 3-hydroxyisovaleric
acid; attention deficit, AD; hyperactivity, H.
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RESULTS OF DIAGNOSTIC LOADING STUDIES
A glucose challenge was administered to all test subjects, reveal-
ing a pathological increase in sera b-OH-b in 16/187 subjects
(Table 3) and elevated sera lactate in 18/187. These results for
glucose loading pointed to mitochondrial disease, although con-
firmatory testing could not be undertaken due to a lack of
monetary support for muscle biopsy from both parents and
insurers.
We instituted a ketogenic diet (KD) in 6/16 patients who had
demonstrated a pathological increase in serum b-OH-b associ-
ated with glucose loading. Although our desire was to implement
the KD in all 16 patients, it is a diet particularly challenging
to implement in autistic patients, and we were only success-
ful in six cases. One of these six patients showed a remarkable
improvement in CARS scale (Table 4) and subsequently medica-
tions (risperidone and hydroxyzine) were stopped. This patient
is currently attending a public elementary school without clinical
problems. Clinical improvements in the remaining 5/6 patients
weremore subtle (Table 4). Additionally, for 5/178 patients, blood
b-OH-b levels were significantly lower in comparison to con-
trol levels following a 12 h fast. Conversely, urine organic acid
analysis and acylcarnitine evaluation in dried blood spots were
normal for all of these patients, thus providing no evidence for
a defect in beta-oxidation. An overview of abnormal biochemical
and loading results is presented in Figure 1.
Table 3 | Evaluation of lactate and beta-hydroxybutyrate after glucose
loading test.
Pat. Pre-GLT Post-GLT Pat. Pre-GLT Post-GLT
no (b-OH-b) (b-OH-b) no (lactate) (lactate)
1 1.45 1.82 1 14 19
2 1.05 1.49 2 10 14
3 1.23 1.65 3 15 21
4 1.45 1.88 4 8 10
5 1.30 1.45 5 10 13
6 1.15 1.34 6 12 17
7 1.35 1.42 7 14 18
8 1.20 1.36 8 14 19
9 1.00 1.25 9 12 14
10 0.90 1.10 10 9 12
11 1.30 1.45 11 8 9
12 1.40 1.60 12 10 13
13 1.25 1.35 13 16 35
14 1.30 1.55 14 15 35
15 1.10 1.25 15 12 29
16 1.35 1.45 16 12 34
Patients with pathologically increased sera beta-hydroxybutyrate and lactate
following glucose loading test (GLT). Patients 13–16 had both increased b-OH-
b (beta-hydroxybutyrate) and lactate. Values for b-OH-b are in mmol/L, while
those for lactate are in mg/dL. According to the kit employed for measurement
of these metabolites, pathological values for b-OH-b pathological are consid-
ered >1.5 mmol/L, while pathological levels of lactate are considered as those
>15 mg/dL. Pathological results for post-GLT lactate are those that exceed 30%
of the pre-GLT lactate value.
FAMILY HISTORIES, CLINICAL FINDINGS, AND DIETARY
CHARACTERISTICS
Twenty-two of 178 test subjects had a family history that was posi-
tive for neurological disease. Additionally, 13/178 subjects had 1st,
2nd, or 3rd degree relatives with comparable symptoms, while
other family members often suffered from other chronic neu-
rological morbidity, including epilepsy, ataxia or mild to severe
developmental delay. Consanguinity was confirmed in the parents
of six patients (1st, 2nd and 3rd degree relatives). Unfortunately
three of these families had children with symptomatology simi-
lar to that of the proband we investigated. Twelve of 178 patients
had clear evidence of facial dysmorphia, including hypertelorism
and low-set ears. With regard to diet, 26/178 subjects showed evi-
dence of dietary intolerance. Of these, 5/26 patients (who also
had abnormal glucose loading results) manifested exacerbation
of symptoms during high carbohydrate intake. Similarly, three
patients who demonstrated decreased blood ketone body pro-
duction following a glucose bolus self-selected a low-fat diet, and
high fat consumption correlated with deterioration in the clin-
ical picture for one of these three, characterized by increased
hyperactivity and stereotypies. Finally, 15/187 patients without
biochemical abnormalities manifested food intolerance, and key
clinical symptoms (hyperactivity, increased stereotypies, sleep
disturbances) were exacerbated with high protein consumption.
NEUROIMAGING ABNORMALITIES
Twenty-five of 187 subjects manifested pathological EEG find-
ings without seizures, the most common feature being beta-
rhythms. Abnormalities of the MRI were found in 12/187
subjects, featuring primarily cerebellar hypoplasia and agene-
sis of the corpus callosum in the absence of specific structural
abnormalities. Additionally, 7/187 patients without pathologi-
cal biochemical findings suffered from epilepsy that was treated
symptomatically with valproate (n = 3), carbamazepine (n = 3)
and oxcarbazepine (n = 1). A comprehensive summary of find-
ings for family history, consanguinity, dysmorphia, imaging
abnormalities and dietary aversions is presented in Table 5.
DISCUSSION
A complex disorder associated with multifactorial inheritance,
autism (or ASD; also pervasive developmental delay) is com-
prised of multiple phenotypic features, the most prominent of
which are behavioral disturbances (e.g., obsessive compulsive
disorder and/or highly ritualistic behavior) and primary distur-
bances of social skills, the latter prominent in adolescents and
adults (Stokstad, 2001; Manzi et al., 2008; Kotulska and Józ´wiak,
2011). For most patients, the primary etiology remains unde-
fined. Conversely, in a small subset of cases there is a clear genetic
etiology, primarily those of a syndromic genetic disorder, includ-
ing Fragile X syndrome, tuberous sclerosis and others (Pickler and
Elias, 2009; Toriello, 2012). Additionally, expanding research has
revealed the presence of ASD in IEM, including phenylketonuria,
disorders of mitochondrial metabolism (Weissman et al., 2008;
Shoffner et al., 2010), defects in the metabolism of purines and
pyrimidines, and disorders of cerebral glucose transport (Schaefer
and Lutz, 2006; Schiff et al., 2010; Zhao et al., 2010). Of interest,
in the rare disorder of GABA metabolism, SSADH deficiency, a
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Table 4 | ASD patients responsive to ketogenic diet implementation.
Pat. no Cardinal symptoms Non-autistic
symptoms
Pre-CARS Age of
treatment
initiation
in years
Post-CARS
6 months
after
treatment
initiation
Cardinal symptoms
6 months after treatment
initiation
1 Hyperactivity, attention deficit, not
responding to verbal cues, no speech,
compulsive behavior, preoccupation
with parts of objects, abnormal sleep
Pathologic EEG 41 3,5 21 No symptoms
2 Hyperactivity, attention deficit, not
responding to verbal cues, no speech,
aggressive or self-injurious behavior
Pathologic MRI 41 6 32 Improvement of all symptoms, no
hyperactivity, no attention deficit
3 Hyperactivity, attention deficit,
sustained inappropriate play,
compulsive behavior, abnormal
speech
Pathologic EEG 41 4 33 Improvement of all symptoms
especially in speech, no
hyperactivity
4 Hyperactivity, attention deficit, not
responding to verbal cues, stereotype
Consanguinity 39 3,5 30 Improvement of all symptoms
5 Hyperactivity, attention deficit, not
responding to verbal cues, no speech,
compulsive behavior, preoccupation
with parts of objects, sustained
inappropriate play
Positive family
history
45 4 40 Minimal improvement of all
symptoms
6 Hyperactivity, attention deficit, no
speech, compulsive behavior,
sustained inappropriate play
Food
intolerance
(aggravation of
symptoms
after
carbohydrate
ingestion)
41 5 37 Moderate improvement in speech
and attention deficit; minimal
improvement of remaining
symptoms
See legend to Table 2 for details. Patients were not undergoing adjuvant therapy during ketogenic diet intervention.
FIGURE 1 | Summary of metabolic abnormalities in the patients evaluated in this study. Abbreviations: IEM, inborn errors of metabolism; 3-OH-IVA, 3
hydroxyisovaleric acid; GLT, glucose loading test; b-OH-b, β-hydroxybutyrate; MC, methylcitrate.
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Table 5 | Distribution of pathological findings corresponding to subgroups depicted in Figure 1.
Number of patients Group A Group B Group C Group D Group E
Ba Bb Ca Cb Cc
PathologicMRI 12 1 2 3 1 5
Pathologic EEG 28 2 (SSADH) 3 1 2 6 2 1 10
Dysmorphia 12 1 1 1 9
Food intolerance 27 1 (PKU) 2 1 3 2 2 4 13
Family history 22 2 1 2 6 1 1 9
Consanguinity 12 1 2 2 7
Diagnosed IEM 5 5
The same patient can have more than one or no pathological findings.
major subset of confirmed adolescent patients suffer from exten-
sive obsession compulsion, frequently characterized as ASD (Pearl
et al., 2011).
In addition to the confirmed cases of IEM that were detected
in the current report (5/178 cases), our cohort analyses included
indirect evidence for IEM without confirmed diagnosis, includ-
ing abnormal responses to glucose loading, response to KD (in
the absence of clinical seizures) and responsiveness to pharmaco-
logical biotin administration. The response to biotin in a subset
of our cohort, despite an absence of defined deficiencies in biotin-
dependent biotinidase or multiple carboxylase enzymes, supports
earlier findings in ASD cohorts revealing nutritional deficiencies
including biotin (Main et al., 2010; Adams et al., 2011). From
the biochemical perspective, it would seem logical to assume
that biotin response and hyperexcretion of 3-OH-IVA in our
cohort are correlated, most likely through biotin-dependent 3-
methylcrotonyl-CoA carboxylase, but currently we have no clear
etiology explaining the response to biotin.
To our knowledge, the existence of Lesch-Nyhan disease or
SSADH deficiency has not been previously detected during
screening of any ASD patient cohort. The rarity of both suggests
that a more discrete screening for these disorders in the ASD pop-
ulation is warranted, at the very least in the Greek population. The
finding of two cases of SSADH deficiency within 187 cases (>1%)
is consistent with the expanding phenotypic observation of OCD
in these patients (Vogel et al., 2012). The current report, there-
fore, may present some justification for the concept of screening
for SSADH deficiency in the autism and ASD populations, espe-
cially in those populations in which autosomal recessive disorders
are expected to have increased prevalence.
The current report represents only the second large scale
evaluation of ASD patients for the presence of IEMs. Schiff
et al. (2011) broadly screened 274 ASD patients for the pres-
ence of IEM, identifying two cases. These included a case of
non-specific urinary creatine excretion and a patient with per-
sistent 3-methylglutaconic aciduria, or less than 1% yield in
their patient cohort. Neither Schiff ’s report nor ours positively
identified patients with mitochondrial disease, creatine trans-
port defects, glucose transport defect or others (e.g., glucose-6-
phosphate dehydrogenase deficiency) which have been previously
documented in ASD patients (Connolly et al., 2010; Guevara-
Campos et al., 2010). This may simply reflect the ethnicity of the
cohorts evaluated, including France and Greece, where incidence/
prevalence of various IEMs will be quite different. Other inves-
tigators have recommended that care be taken in considering
screening for IEM in ASD patients (Wang et al., 2010), and Moss
and Howlin (2009) have appropriately cautioned that correla-
tion of behavioral similarities between ASD and those observed
in genetically-determined syndromes (e.g., Fragile X, Angelman,
etc.) be carefully interpreted. Nonetheless, our report suggests
that further consideration be given to the selected analysis of
IEM in ASD patients, and that those studies might benefit from
the broadest coverage of ethnic and regional groups possible,
especially in populations for whom recessive disorders have an
increased incidence. Broad screening evaluations such as these
might be justifiable in helping to identify genetic subsets of ASD,
providing genetic counseling opportunities for affected families,
and presenting treatment options for those disorders for which
therapeutic options are available. Clearly, the key outcome of our
investigation is the identification of biomarker (3-OH-IVA and
b-OH-b) with therapeutic relevance (biotin, KD) for patients
with ASD, suggesting that our results should be investigated in
additional ASD cohorts.
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